Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 631 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetes in Adults Clear all
Completed No phase listed Observational Accepts healthy volunteers

Assessing Inherited Markers of Metabolic Syndrome in the Young

NCT00966407
View directory record Official record
Conditions
Metabolic Syndrome, Diabetes Mellitus, Type 2, Obesity
Interventions
Not listed
Lead sponsor
Eric Hoffman
Other
Eligibility
18 Years to 35 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 23, 2026, 8:15 PM EDT
Recruiting Not applicable Interventional

Dietary Insights and Nutritional Education in Adults on GLP-1 Therapy

NCT07518407
View directory record Official record
Conditions
Obesity Type 2 Diabetes Mellitus, Obesity
Interventions
SWITCH Diets - Mobile Nutrition Behavioral Intervention
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Terminated Phase 1 Interventional Results available

Multiple Dose Study Of PF-05231023 In Obese Adult Subjects

NCT01923389
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Placebo, 100 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Sep 23, 2026, 8:15 PM EDT
Active, not recruiting Not applicable Interventional

A Randomized Parallel Clinical Trial of AIDANET, an Automated Insulin Delivery Algorithm, in Fully Closed-Loop Vs Hybrid Closed-Loop Mode In Adults With Type 1 Diabetes (AIDANET At Home)

NCT07039617
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
AIDANET + FCL, AIDANET + HCL, AIDANET in FCL-HCL-mixed mode, Automated Insulin Delivery (AID) (usual care)
Device · Other
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Completed No phase listed Observational

Transition to Adult Care in Type 1 Diabetes

NCT03886974
View directory record Official record
Conditions
Type1diabetes
Interventions
Not listed
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Results available

A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus

NCT01044537
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, PF-04937319
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Phoenix, Arizona • Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 23, 2026, 8:15 PM EDT
Withdrawn Not applicable Interventional

Embecta AID System in Adults With Type 2 Diabetes

NCT06692153
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 DM, T2DM With Inadequate Glycemic Control, T2DM (Type 2 Diabetes Mellitus), T2D, T2DM
Interventions
An AID System., Standard of Care (SC)
Device · Other
Lead sponsor
Embecta Corp.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Palo Alto, California • Walnut Creek, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 3 Interventional

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

NCT05803421
View directory record Official record
Conditions
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
Interventions
Orforglipron, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
173
States / cities
Daphne, Alabama • Mobile, Alabama • Pelham, Alabama + 149 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Results available

A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

NCT00886821
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CVX-096
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Miami Gardens, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available

A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community

NCT02114814
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes self-management program for Hispanics and their families, General health educational program for Hispanics and their families
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 99 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring

NCT05935514
View directory record Official record
Conditions
Diabetes Mellitus, Type 2 Diabetes, Obesity
Interventions
WW Intervention, Usual Care
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 69 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Stanford, California • Baton Rouge, Louisiana • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Chlorthalidone in Type 1 Diabetes

NCT03325114
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypercalciuria
Interventions
Chlorthalidone
Drug
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

This Study Assessed the Impact of Diet on Gastric Emptying Time and Metabolic Flexibility

NCT03630263
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2, Appetitive Behavior
Interventions
Raw Corn Starch, No Raw Corn Starch
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

NCT00625859
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK189075, Bupropion, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Reducing Stress in Adolescents and Young Adults With Type 1 Diabetes to Improve Diabetes Care

NCT02760303
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Cognitive Behavioral Therapy, Mindfulness Based Stress Reduction, Diabetes Support and Education
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
16 Years to 20 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional

Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM

NCT02581657
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PE0139 Injection, Placebo Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Anniston, Alabama • Huntington Park, California • Bradenton, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 23, 2026, 8:15 PM EDT
Not listed Phase 2 Interventional

An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

NCT03279263
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MLR-1023, Placebo
Drug · Other
Lead sponsor
Melior Pharmaceuticals
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 23, 2026, 8:15 PM EDT
Not yet recruiting Phase 2 Interventional

Verapamil Effect in Cystic Fibrosis-related Dysglycemia

NCT07688070
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance
Interventions
Verapamil Hydrochloride
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Recruiting Not applicable Interventional

The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV

NCT07226128
View directory record Official record
Conditions
HIV, Depression in Adults, Insulin Resistance, Cognitive Behavior Therapy
Interventions
Internet cognitive behavioral therapy (iCBT-D), Active Control (AC)
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
31
States / cities
Santa Barbara, California • Santa Clarita, California • Aurora, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Active, not recruiting Not applicable Interventional

Diabetes Prevention in Hispanic Adults Using Constant Glucose Monitors

NCT06864728
View directory record Official record
Conditions
Prediabetes / Type 2 Diabetes
Interventions
Video Diabetes Education, In person or virtual diabetes education
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Active, not recruiting Phase 2 Interventional

AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034
View directory record Official record
Conditions
Wolfram Syndrome
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
17 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of Simvastatin and Albiglutide

NCT01147692
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
simvastatin plus albiglutide
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Prebiotics, Gut Microbiota, and Cardiometabolic Health

NCT02346838
View directory record Official record
Conditions
Prediabetes
Interventions
Inulin, Placebo
Dietary Supplement
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
40 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 23, 2026, 8:15 PM EDT